At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 160 enrolled
Drug / intervention
Sonidegib Phosphate Capsulesdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-Label, Single-Arm, Multi-Center, Phase IV Efficacy and Safety Study of Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
In Brief
A Phase 4 clinical trial evaluating Sonidegib Phosphate Capsules for Carcinoma, Basal Cell (BCC). Completed, enrolled 160 participants across 1 site.
Detailed Summary
This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation therapy, curative surgery or other local therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Basal Cell (BCC)
CountriesChina
Timeline
Phase 4CompletedFinished
202420252026
Enrollment StartJun 2023
First PostedMar 2025
Primary CompletionAug 2025
TodayJul 2026
First PostedMar 18, 2025
Enrollment StartJun 21, 2023
Primary CompletionAug 26, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 1.3 years ago
Interventions
Sonidegib Phosphate Capsulesdrug
Sonidegib should be taken 1 hour before or 2 hours after a breakfast